# Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

> **NCT01037309** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 18 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** PRO044 SC
- **DRUG:** PRO044 IV

## Key facts

- **NCT ID:** NCT01037309
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01037309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01037309, "Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01037309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*